Kashmira Mangavkar’s Post

In Pharmacoeconomics, where every decision has profound implications for patient outcomes, healthcare expenditures, and societal well-being, the alignment of product value proposition and decision-making is paramount. A product’s value proposition serves as the cornerstone of this alignment, encapsulating the perceived benefits, costs, and overall value of pharmaceutical interventions. However, the interpretation of value is multifaceted and subjective, influenced by diverse stakeholders with varying priorities and perspectives. From healthcare providers striving to optimize patient care within budget constraints to payers navigating the complexities of reimbursement decisions, each entity brings its own dialect to the conversation. Moreover, the dynamics of decision-making in Pharmacoeconomics are further complicated by evolving market dynamics, regulatory requirements, and technological advancements. In this complex ecosystem, clarity in communication and a shared understanding of value proposition become indispensable for informed decision-making. Hussain Al-Omar, Associate Professor of Pharmacoeconomics at King Saud University, will explore this compelling question, using real-world case studies to engage in collaborative discussions. Visit www.menahta.com and register now! #MENAHTAForum #HTAexpert #MENAHTAForum2024 #Pharmacoeconomics #ValueProposition

In Pharmacoeconomics, where every decision has profound implications for patient outcomes, healthcare expenditures, and societal well-being, the alignment of product value proposition and decision-making is paramount. A product’s value proposition serves as the cornerstone of this alignment, encapsulating the perceived benefits, costs, and overall value of pharmaceutical interventions. However, the interpretation of value is multifaceted and subjective, influenced by diverse stakeholders with varying priorities and perspectives. From healthcare providers striving to optimize patient care within budget constraints to payers navigating the complexities of reimbursement decisions, each entity brings its own dialect to the conversation. Moreover, the dynamics of decision-making in Pharmacoeconomics are further complicated by evolving market dynamics, regulatory requirements, and technological advancements. In this complex ecosystem, clarity in communication and a shared understanding of value proposition become indispensable for informed decision-making. Dr.Hussain Al-Omar, Associate Professor of Pharmacoeconomics at King Saud University, will explore this compelling question, using real-world case studies to engage in collaborative discussions. Visit www.menahta.com and register now! Follow MENAHTA Forum on LinkedIn for more updates. #MENAHTAForum #HTAexpert #MENAHTAForum2024 #Pharmacoeconomics #ValueProposition

🌍 Exploring Managed Entry Agreements (MEAs) for Health Technologies in the MENA Region 🏥by Rita El Ojeil (ريتا العجيل) https://lnkd.in/dkRD92At We're excited to share our latest article on Market Access Today, diving deep into the complexities and opportunities of Managed Entry Agreements (MEAs) for health technologies in the Middle East and North Africa (MENA) region. As healthcare systems in the MENA region evolve, the need for innovative solutions to manage the introduction of high-cost therapies becomes critical. This article explores the dos and don'ts of MEAs, providing valuable insights into how governments and pharmaceutical companies can collaborate to ensure that patients gain timely access to cutting-edge treatments while managing financial risks. 🔍 Key Highlights: The growing importance of MEAs in the MENA region. Types and benefits of MEAs, including Value-Based Agreements (VBAs) and Performance-Based Agreements (PBAs). A comparative analysis of MEA adoption across MENA countries. Practical advice on the design and implementation of MEAs. Whether you're a healthcare professional, policymaker, or involved in pharmaceutical market access, this article provides essential guidance on navigating MEAs in a rapidly changing healthcare landscape. #MarketAccess #HealthcareInnovation #Pharmaceuticals #MEA #MiddleEast #NorthAfrica #HealthTechnologies #ValueBasedAgreements #PerformanceBasedAgreements

We have compiled the week's top news for you at Market Access Today! - In a pivotal moment that may herald a new phase for China’s burgeoning pharmaceutical industry, both domestic and multinational, recent developments suggest the Chinese government is poised to implement a series of policies aimed at stimulating innovation within this critical pharmaceutical industry... (https://lnkd.in/dJqUAKqH) - In a groundbreaking simulation study, researchers delved into the ramifications of adopting the EUnetHTA21 methodologies for the evaluation of oncology medicines within the European Union... (https://lnkd.in/dcJ-vbNk) - The Finnish Institute for Health and Welfare (THL) has voiced its support for a proposal that has recently come to public attention, advocating for the imposition of stricter taxation measures on foods that are harmful to health, based on their contents of sugar, salt, and fat... (https://lnkd.in/gTdviChn) - The decision by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to adopt the International Medical Device Regulators Forum (IMDRF) risk categorization for Software as a Medical Device (SaMD) represents a significant shift towards standardizing the regulatory landscape across borders, thereby facilitating smoother market access for SaMD products worldwide... (https://lnkd.in/ddjQy-TA) - The Pharmaceutical Benefits Scheme (PBS) review of medications for endometriosis, spearheaded by the Pharmaceutical Benefits Advisory Committee (PBAC) in December 2022, has cast a significant spotlight on the healthcare needs-of individuals grappling with endometriosis and associated conditions across Australia... (https://lnkd.in/dYB54r9c) Stay Informed, Stay Ahead with Market Access Today: marketaccesstoday.com #marketacces #reimbursementpolicies #patientaccessschemes #healthcareindustry #pricing #healtheconomics #pharmacoeconomics #health #pharmaceuticals #medicaldevices #HEOR #HTA #RWE #insights #trends #updates 

Pharmaceutical Industry Growth: Just the Right Pill for Saudi Arabia’s Healthcare Goals. Saudi Arabia’s Vision 2030 is Transforming Healthcare! As the Kingdom invests heavily in healthcare infrastructure, the demand for pharmaceuticals is soaring. The local pharma market is expected to reach $5.53 billion by 2024 and grow to $6.93 billion by 2029. 🔹 Fueling Local Innovation: The Kingdom’s push for localization means more than just numbers. By producing key medications locally, Saudi Arabia is reducing costs, enhancing access, and making the healthcare sector more resilient. Notable collaborations like Boehringer Ingelheim’s partnership with Alpha Pharma are setting the stage for Saudi Arabia to become a regional biotech hub. 🔹 Empowering the Economy: The Saudi government is driving this transformation with incentives, tax breaks, and streamlined regulations. By 2030, these initiatives will generate 11,000 jobs and contribute $34.6 billion to the non-oil GDP, firmly positioning the Kingdom as a global leader in pharmaceutical manufacturing and research. 🔹 Beyond the Pill: Localization isn't just about producing meds—it’s about securing a sustainable, innovative future for Saudi Arabia's healthcare sector. With the right policies and partnerships, the Kingdom is set to achieve its ambitious healthcare goals and solidify its role as a leader in the life sciences. Let’s connect and discuss how this evolving landscape is creating opportunities for investors, businesses, and communities in Saudi Arabia! #SaudiVision2030 #PharmaceuticalIndustry #HealthcareInnovation #SaudiArabia #BusinessStrategy #RealEstateAdvisory #InvestmentOpportunities #shan

Post 1: Understanding the EDQM: A Pillar of Public Health 🌍 Hello LinkedIn Community! Today, I want to shed light on the European Directorate for the Quality of Medicines & HealthCare (EDQM) and its vital role in public health. Here are some key points to enhance our knowledge about this important organization: 🔍 What is the EDQM? The EDQM is a key body of the Council of Europe, established under the Convention on the Elaboration of a European Pharmacopoeia, signed in 1964. Its primary mission is to ensure the quality of medicines and healthcare across Europe, working collaboratively with various stakeholders, including governments, healthcare professionals, and the pharmaceutical industry. 🛠️ What Does the EDQM Do? European Pharmacopoeia: The EDQM develops and maintains the European Pharmacopoeia, a vital reference for quality standards in medicines. Certification of Suitability (CEP): It provides a procedure for certifying that substances used in medicines meet the required quality standards. OMCL Network: The EDQM supports the Official Medicines Control Laboratories (OMCL) Network, which ensures the quality and safety of medicines through independent testing. Substances of Human Origin: The organization oversees activities related to the quality and safety of substances derived from human origin, such as blood and tissues. Consumer and Pharmaceutical Care: The EDQM promotes best practices in pharmaceutical care and consumer health, ensuring that patients receive safe and effective treatments. 🤝 Let’s Discuss: I believe understanding the role of organizations like the EDQM is essential for anyone involved in healthcare. What are your thoughts on the importance of quality standards in medicines? I’d love to hear your insights in the comments! Together, let’s advocate for better health for all! 💪✨ #PublicHealth #EDQM #QualityStandards #Healthcare #Collaboration #Pharmaceuticals #Regulatoryaffairs

Check out last week's top stories from Market Access Today! #marketaccess #reimbursement #pricing

With the European Medicines Agency’s PMS now live, data enrichment deadlines are approaching fast. Is your portfolio prepared? ⏳ Our handy timeline infographic offers a clear roadmap for meeting upcoming IDMP deadlines. Download the full timeline on the Ennov blog: https://lnkd.in/gSJYv4yh #IDMP #EMA #LifeSciences #RegulatoryAffairs

Did you know that all delegates who are registered to attend the SAPICS 2024 conference can book a seat at a workshop of their choice on Sunday the 9th of June?   Tamara Hafner and Dr Andrew Brown will be presenting Workshop 8: The Nexus of Pharmaceutical Systems and Health Supply Chain Management. What is Needed to Ensure well-functioning supply chains?   Sustainably ensuring equitable access to and appropriate use of safe and quality-assured medicines demands a comprehensive view that situates health supply chains within strong pharmaceutical systems, as a part of the broader health system. USAID MTaPS and its predecessor programs have developed a pharmaceutical system strengthening (PSS) approach that recognizes health supply chains as one of several elements that work in concert to get safe, quality-assured medicines to the population and ensure that they are used appropriately. Participants will learn about the PSS approach and available tools and resources that they can adapt in their health system context.   Learn more about all 11 workshop workshops on offer: https://lnkd.in/dv3_W8yC   The 2024 SAPICS Conference will be held in association with the Southern African Association of Freight Forwarders NPC In view of the demand for workshop attendance and the unfortunate rate of no-shows, there is a non-refundable charge of R350.00 (excl. VAT) per person per workshop. Organised by: Upavon Management Taking place at Century City Conference Centre, Cape Town, South Africa  #SAPICS2024 #SupplyChainMetamorphosis #SupplyChainConference #CapeTown #supplychainmanagement #speakers

AfriSummit 2024: Harmonizing Health Through Unified Regulations and Pharma Innovation On November 6th, 2024, AfriSummit 2024 brought together over 300 professionals from the pharmaceutical and medical device industries and 80 international experts at the Grand Nile Tower. Hosted by PharmaReg and MedDevReg, the four-day hybrid event emphasized Africa’s commitment to harmonizing healthcare regulations and fostering innovation in drug trials and regulatory practices. Key Highlights: ▪️ Hands-on Training: Workshops focused on eCTD and Pharmacovigilance emphasized practical skills for compliance and innovation. ▪️ Leadership in Action: Dr. Rasha Ziada of the Egyptian Drug Authority (EDA) stressed the responsibility of achieving WHO Maturity Level 3, extending EDA's regulatory expertise to support other African nations. ▪️ Collaborative Solutions: Roundtable discussions united African National Regulatory Authorities (NRAs) with industry leaders, identifying opportunities to strengthen healthcare regulations across the continent. ▪️ Calls for Harmonization: Dr. Mona Al Moussli, Chairman of AfriSummit, highlighted the urgent need for unified regulatory frameworks, declaring, “Harmonized practices are key to advancing Africa’s healthcare systems.” At VICORE HEALTH LTD, whilst we could unfortunately not attend, we support and align with these transformative efforts, while offering expertise in navigating regulatory landscapes and fostering innovation in healthcare. Manufacturers seeking to adapt to Africa’s evolving regulatory environment are encouraged to connect with us for tailored solutions. https://lnkd.in/ewr9iAEB #AfriSummit2024 #HealthcareInnovation #RegulatoryHarmonization #PharmaAfrica #VicoreHealth